← FDA DRUG APPROVALS

FDA NDA · NDA218549

ZUNVEYL

benzgalantamine

Sponsor: ALPHA COGNITION

APPLICATION
NDA218549
TYPE
NDA
ORIGINAL APPROVAL
2024-07-26
LATEST ACTION
2024-07-26
ROUTE
ORAL
DOSAGE FORM
TABLET, DELAYED RELEASE
MARKETING STATUS
Prescription

Products

ZUNVEYL · ReferencePrescription
BENZGALANTAMINE GLUCONATE EQ 10MG BASE · TABLET, DELAYED RELEASE · ORAL
ZUNVEYL · ReferencePrescription
BENZGALANTAMINE GLUCONATE EQ 15MG BASE · TABLET, DELAYED RELEASE · ORAL
ZUNVEYL · ReferencePrescription
BENZGALANTAMINE GLUCONATE EQ 5MG BASE · TABLET, DELAYED RELEASE · ORAL

Approval history

2024-07-26Type 2 - New Active Ingredient and Type 3 - New Dosage Form · Original · standardReviewAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →